Biomarkers in Huntington's and Parkinson's Disease
Identifieur interne : 000608 ( Main/Curation ); précédent : 000607; suivant : 000609Biomarkers in Huntington's and Parkinson's Disease
Auteurs : Gráinne C. O Eeffe [Royaume-Uni] ; Andrew W. Michell [Royaume-Uni] ; Roger A. Barker [Royaume-Uni]Source :
- Annals of the New York Academy of SciencesBiomarkers in Brain Disease [ 0077-8923 ] ; 2009-10.
English descriptors
- KwdEn :
Abstract
Parkinson's (PD) and Huntington's disease (HD) are chronic neurodegenerative conditions of the brain with a variety of clinical presentations including a disorder of movement and a range of nonmotor deficits. HD is genetic in origin and the causative gene and protein known, namely mutant Huntingtin, which leads to widespread early neuronal dysfunction and death throughout the brain. In contrast, the etiology of sporadic PD is unknown, and the pathology targets the nigrostriatal dopaminergic neurons with the formation of α‐synuclein positive Lewy bodies. In both diseases, the ability to accurately diagnose the disease in the early stages and monitor progression over time remains a major challenge given the majority of the pathology is sited deep within the CNS. This challenge has gained extra significance as the development of disease‐modifying drugs starts to emerge into the clinic. To this end, there is a need to find biomarkers that will help in the accurate diagnosis of the disease and/or prediction of its clinical onset as well as biomarkers that are able to faithfully track disease progression independent of any symptomatic effects of any therapies. In addition, these same markers may also help stratify each of these heterogeneous disorders into specific subtypes that share particular clinical and pathological characteristics.
Url:
DOI: 10.1111/j.1749-6632.2009.04943.x
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000695
Links to Exploration step
ISTEX:7A3E7D44B7CB0D6368EE5B248E62A5AE16044A2ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biomarkers in Huntington's and Parkinson's Disease</title>
<author><name sortKey="O Eeffe, Grainne C" sort="O Eeffe, Grainne C" uniqKey="O Eeffe G" first="Gráinne C." last="O Eeffe">Gráinne C. O Eeffe</name>
<affiliation wicri:level="1"><mods:affiliation>Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Michell, Andrew W" sort="Michell, Andrew W" uniqKey="Michell A" first="Andrew W." last="Michell">Andrew W. Michell</name>
<affiliation wicri:level="1"><mods:affiliation>Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Barker, Roger A" sort="Barker, Roger A" uniqKey="Barker R" first="Roger A." last="Barker">Roger A. Barker</name>
<affiliation wicri:level="1"><mods:affiliation>Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7A3E7D44B7CB0D6368EE5B248E62A5AE16044A2E</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1111/j.1749-6632.2009.04943.x</idno>
<idno type="url">https://api.istex.fr/document/7A3E7D44B7CB0D6368EE5B248E62A5AE16044A2E/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">000695</idno>
<idno type="wicri:Area/Main/Curation">000608</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Biomarkers in Huntington's and Parkinson's Disease</title>
<author><name sortKey="O Eeffe, Grainne C" sort="O Eeffe, Grainne C" uniqKey="O Eeffe G" first="Gráinne C." last="O Eeffe">Gráinne C. O Eeffe</name>
<affiliation wicri:level="1"><mods:affiliation>Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Michell, Andrew W" sort="Michell, Andrew W" uniqKey="Michell A" first="Andrew W." last="Michell">Andrew W. Michell</name>
<affiliation wicri:level="1"><mods:affiliation>Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Barker, Roger A" sort="Barker, Roger A" uniqKey="Barker R" first="Roger A." last="Barker">Roger A. Barker</name>
<affiliation wicri:level="1"><mods:affiliation>Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the New York Academy of SciencesBiomarkers in Brain Disease</title>
<idno type="ISSN">0077-8923</idno>
<idno type="eISSN">1749-6632</idno>
<imprint><publisher>Blackwell Publishing Inc</publisher>
<pubPlace>Malden, USA</pubPlace>
<date type="published" when="2009-10">2009-10</date>
<biblScope unit="volume">1180</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="97">97</biblScope>
<biblScope unit="page" to="110">110</biblScope>
</imprint>
<idno type="ISSN">0077-8923</idno>
</series>
<idno type="istex">7A3E7D44B7CB0D6368EE5B248E62A5AE16044A2E</idno>
<idno type="DOI">10.1111/j.1749-6632.2009.04943.x</idno>
<idno type="ArticleID">NYAS4943</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0077-8923</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Huntington's disease</term>
<term>Parkinson's disease</term>
<term>biomarker</term>
<term>imaging</term>
<term>motor measures</term>
<term>“wet” biomarker</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's (PD) and Huntington's disease (HD) are chronic neurodegenerative conditions of the brain with a variety of clinical presentations including a disorder of movement and a range of nonmotor deficits. HD is genetic in origin and the causative gene and protein known, namely mutant Huntingtin, which leads to widespread early neuronal dysfunction and death throughout the brain. In contrast, the etiology of sporadic PD is unknown, and the pathology targets the nigrostriatal dopaminergic neurons with the formation of α‐synuclein positive Lewy bodies. In both diseases, the ability to accurately diagnose the disease in the early stages and monitor progression over time remains a major challenge given the majority of the pathology is sited deep within the CNS. This challenge has gained extra significance as the development of disease‐modifying drugs starts to emerge into the clinic. To this end, there is a need to find biomarkers that will help in the accurate diagnosis of the disease and/or prediction of its clinical onset as well as biomarkers that are able to faithfully track disease progression independent of any symptomatic effects of any therapies. In addition, these same markers may also help stratify each of these heterogeneous disorders into specific subtypes that share particular clinical and pathological characteristics.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000608 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000608 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:7A3E7D44B7CB0D6368EE5B248E62A5AE16044A2E |texte= Biomarkers in Huntington's and Parkinson's Disease }}
This area was generated with Dilib version V0.6.23. |